

# CANADIAN CANCER SOCIETY

55 St. Clair Avenue West Suite 300 Toronto, ON M4V 2Y7 President & CEO: Anne Vezina Board Chair: Marc Genereux

Website: www.cancer.ca Charitable Reg. #: 11882 9803 RR0001

#### **Financial Transparency**








Audited financial statements for current and previous years available on the charity's website


# **Program Cost Coverage**



Funding Reserves

Program Costs

### **Spending Breakdown**



Full-time Staff # 1,191
Avg. Compensation \$58,471
Top 10 Staff Salary Range

\$350k +	
\$300k-\$350k	2
\$250k-\$300k	1
\$200k-\$250k	5
\$160k-\$200k	2
\$120k-\$160k	
\$80k-\$120k	
\$40k-\$80k	
< \$40k	

Information from most recent CRA Charities Directorate filings for F2011

# Sector: Health - Cancer Operating Charity

About Canadian Cancer Society: Canadian Cancer Society (CCS) is a single legal entity, operating as one national office and 10 regional divisions. Although the national office sets the overall corporate strategy, the divisions and sub branches have a tremendous amount of autonomy to decide how to best implement the strategy. The Society has three priority areas: to fund research in all aspects of cancer, to advocate for healthy public policy and access to quality care, and to provide programs in prevention, information and support to Canadians. CCS is the largest national charitable funder of cancer research in Canada. CCS has changed its research program to garner stronger support for larger and longer research projects, which helps ease the administrative burden on researchers. Each division has discretion about how to best support cancer patients. Support varies as needed to address local health care. Last year CCS funded 336 research projects that led to 565 scientific papers being published in peer-reviewed journals. CCS's new online sharing community, Cancerconnection.ca, has over 17,000 visits since March 2011. In F2012, 27,000 smokers were helped by the Society's quit smoking programs.

Financial Review: Administrative costs are 4% of total revenue with fundraising costs representing 36% of donations and special events. CCS has enough funding reserves to cover 127% of annual program costs. Out of the \$160m funding reserve, \$36m was committed to research and \$7.8m was externally-endowed. Compensation data includes all regional divisions as well as the national office.

#### **Financial Ratios**

Fiscal year ending January 31st	2012	2011	2010
Administrative costs as % of revenues	3.8%	3.7%	4.9%
Fundraising costs as % of donations	35.7%	37.7%	41.0%
Program cost coverage (%)	126.7%	118.7%	125.1%
Summary Financial Statements			
All figures in \$000s	2012	2011	2010
Donations	104,217	94,260	90,266
Government funding	11,571	9,295	10,141
Lotteries (net)	8,690	880	2,795
Special events & other	84,218	83,948	84,630
Investment income	3,119	4,240	5,888
Total revenues	211,815	192,623	193,720
Program costs	126,258	128,484	129,507
Administrative costs	8,025	7,061	9,269
<u>Fundraising costs</u>	64,672	64,736	68,183
Cash flow from operations	12,860	(7,658)	(13,239)
Funding reserves	159,916	152,515	162,059

Note: Deferred revenues have been adjusted to appear in the year received, increasing revenues in F2012 by \$2.0m and decreasing revenues in F2011 by \$0.2m and F2010 by \$3.0m.



#### **CANADIAN CANCER SOCIETY**

Year ending January 31st

Community ownership

(local support \$ / pop.)

Program Data	2012	2011	2010
Program costs	126,258,000	128,484,000	129,507,000
Program hours	n/a	n/a	n/a
Total volunteers	170,000	170,000	170,000
Volunteer hours	n/a	n/a	n/a
Volunteer turnover rate (%)	n/a	n/a	n/a
Clients served	n/a	n/a	n/a
Program hours / client	n/a	n/a	n/a
Program costs / hour	n/a	n/a	n/a
Program costs / client	n/a	n/a	n/a
Charity Analysis	2012	2011	2010
Revenues (less interest income)	208,696,000	188,383,000	187,832,000
Value of donated time	n/a	n/a	n/a
Donated goods and services	2,421,000	8,891,000	1,244,000
Charity value	211,117,000	197,274,000	189,076,000
Administrative costs (as % of charity value)	4%	4%	5%
Local support (\$)	190,856,000	187,099,000	176,140,000
Community size (population)	33,863,000	33,477,000	33,096,000

\$5.64

History: In 1929, the Saskatchewan Medical Association formed Canada's first cancer committee. In 1931, the Canadian Medical Association's National Study Committee on Cancer was formed. CCS was officially formed in 1938. In 1947, the National Cancer Institute of Canada (NCIC) was formed through an agreement between the CCS and the Federal Department of Health and Welfare. In 2009, NCIC was fully integrated into CCS.

Management: The current acting President and CEO is Anne Vezina. All six members of the senior leadership team of the National Office have been with CCS for over five years, with an average of 10 years. At the Divisional level, the vast majority of the CEOs and Executive Directors have been with CCS for at least five years.

Social Results: There is strong evidence suggesting that CCS's contribution to the formation, building, maintenance and leading of a tobacco advocacy partnership was successful at influencing tobacco policy change and Canadians' perception of smoking over the past 25 years. In F2012, 5,044 people received financial assistance, 23,195 were helped by the Volunteer Drive program, 8,733 were lodged in a CCS lodge, 7,993 clients received prostheses, wigs, or other supplies, and 42,039 clients received one-on-one information and support services. CCS is encouraging appropriate screening of Canadians, which has the potential to save thousands of lives.

\$5.59

\$5.32

Community Need: This year, 75,700 deaths will occur from cancer in Canada. Of the newly diagnosed cases, more than one-half will be lung, colorectal, prostate and breast cancers. On the basis of current incidence rates, 40% of Canadian women and 45% of men will develop cancer during their lifetime.

Funding Need: CCS programs would benefit from an increase to \$160m-\$200m per year to further fund research, prevention and relay CCS' mission.

Investment Highlights: CCS is by far the largest charity in the cancer sector. It is involved with all aspects of cancer, providing a one-stop-shop for donors. CCS selects promising research projects based on a rigorous peer review process. CCS's advocacy and lobbying programs have been instrumental in cancer prevention as well as implementing programs to assist cancer patients. CCS funded a trial led by the NCIC Clinical Trials Group; the resulting drug exemestane reduces the risk of breast cancer by 65% compared with a placebo. This discovery was recognized by the American Society of Clinical Oncology as one of the world's most important cancer treatment breakthroughs in 2011. CCS is planning a special campaign to raise money for relatively underfunded cancers.

Investment Risks: It is very difficult to quantify CCS's total impact in preventing cancer and treating and supporting cancer patients. Fundraising costs are high, although they have been decreasing over the past three years.

Karen Greve Young (kyoung@charityintelligence.ca), Arun Lamba (alamba@charityintelligence.ca)

August 29, 2012